nodes	percent_of_prediction	percent_of_DWPC	metapath
Plerixafor—CXCR4—endothelium—systemic scleroderma	0.0693	0.265	CbGeAlD
Plerixafor—CXCR4—blood vessel—systemic scleroderma	0.0639	0.244	CbGeAlD
Plerixafor—CXCR4—connective tissue—systemic scleroderma	0.0328	0.125	CbGeAlD
Plerixafor—CXCR4—smooth muscle tissue—systemic scleroderma	0.03	0.114	CbGeAlD
Plerixafor—CXCR4—digestive system—systemic scleroderma	0.0237	0.0904	CbGeAlD
Plerixafor—CXCR4—Hematopoietic Stem Cell Differentiation—CSF1—systemic scleroderma	0.0236	0.156	CbGpPWpGaD
Plerixafor—CXCR4—tendon—systemic scleroderma	0.0225	0.086	CbGeAlD
Plerixafor—CXCR4—lung—systemic scleroderma	0.0198	0.0755	CbGeAlD
Plerixafor—CXCR4—CXCR4-mediated signaling events—RHOB—systemic scleroderma	0.0126	0.0833	CbGpPWpGaD
Plerixafor—CXCR4—Hematopoietic Stem Cell Differentiation—IL1A—systemic scleroderma	0.0116	0.0766	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—CSK—systemic scleroderma	0.0115	0.0759	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—CD247—systemic scleroderma	0.0108	0.0714	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—BLK—systemic scleroderma	0.01	0.066	CbGpPWpGaD
Plerixafor—CXCR4—HIF-1-alpha transcription factor network—EDN1—systemic scleroderma	0.00782	0.0516	CbGpPWpGaD
Plerixafor—CXCR4—Syndecan-4-mediated signaling events—MMP9—systemic scleroderma	0.00682	0.045	CbGpPWpGaD
Plerixafor—CXCR4—Chemokine receptors bind chemokines—CCL2—systemic scleroderma	0.00609	0.0402	CbGpPWpGaD
Plerixafor—CXCR4—Hematopoietic Stem Cell Differentiation—IL1B—systemic scleroderma	0.00605	0.0399	CbGpPWpGaD
Plerixafor—CXCR4—HIV Infection—CD247—systemic scleroderma	0.00508	0.0335	CbGpPWpGaD
Plerixafor—CXCR4—Cardiac Progenitor Differentiation—TGFB1—systemic scleroderma	0.00375	0.0248	CbGpPWpGaD
Plerixafor—CXCR4—Peptide ligand-binding receptors—EDN1—systemic scleroderma	0.00335	0.0222	CbGpPWpGaD
Plerixafor—CXCR4—CXCR4-mediated signaling events—MMP9—systemic scleroderma	0.00315	0.0208	CbGpPWpGaD
Plerixafor—CXCR4—Peptide ligand-binding receptors—CCL2—systemic scleroderma	0.00229	0.0151	CbGpPWpGaD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—EDN1—systemic scleroderma	0.00225	0.0149	CbGpPWpGaD
Plerixafor—Connective tissue disorder—Mycophenolate mofetil—systemic scleroderma	0.0019	0.00324	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—RHOB—systemic scleroderma	0.0019	0.0125	CbGpPWpGaD
Plerixafor—Constipation—Captopril—systemic scleroderma	0.00189	0.00323	CcSEcCtD
Plerixafor—Flatulence—Lisinopril—systemic scleroderma	0.00189	0.00323	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Leflunomide—systemic scleroderma	0.00189	0.00322	CcSEcCtD
Plerixafor—Discomfort—Leflunomide—systemic scleroderma	0.00188	0.0032	CcSEcCtD
Plerixafor—CXCR4—Disease—SMAD7—systemic scleroderma	0.00188	0.0124	CbGpPWpGaD
Plerixafor—Skin disorder—Azathioprine—systemic scleroderma	0.00188	0.0032	CcSEcCtD
Plerixafor—Loss of consciousness—Mycophenolic acid—systemic scleroderma	0.00187	0.00319	CcSEcCtD
Plerixafor—Dry mouth—Leflunomide—systemic scleroderma	0.00186	0.00317	CcSEcCtD
Plerixafor—Vomiting—Pentoxifylline—systemic scleroderma	0.00186	0.00317	CcSEcCtD
Plerixafor—Rash—Pentoxifylline—systemic scleroderma	0.00184	0.00314	CcSEcCtD
Plerixafor—Dermatitis—Pentoxifylline—systemic scleroderma	0.00184	0.00314	CcSEcCtD
Plerixafor—Headache—Pentoxifylline—systemic scleroderma	0.00183	0.00312	CcSEcCtD
Plerixafor—Anaphylactic shock—Leflunomide—systemic scleroderma	0.00182	0.00311	CcSEcCtD
Plerixafor—Feeling abnormal—Captopril—systemic scleroderma	0.00182	0.00311	CcSEcCtD
Plerixafor—Arthralgia—Mycophenolic acid—systemic scleroderma	0.00182	0.00309	CcSEcCtD
Plerixafor—Gastrointestinal pain—Captopril—systemic scleroderma	0.00181	0.00309	CcSEcCtD
Plerixafor—Asthenia—Mometasone—systemic scleroderma	0.00181	0.00308	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—systemic scleroderma	0.0018	0.00307	CcSEcCtD
Plerixafor—Discomfort—Mycophenolic acid—systemic scleroderma	0.00179	0.00306	CcSEcCtD
Plerixafor—Nervous system disorder—Leflunomide—systemic scleroderma	0.00179	0.00305	CcSEcCtD
Plerixafor—Pruritus—Mometasone—systemic scleroderma	0.00178	0.00304	CcSEcCtD
Plerixafor—Ill-defined disorder—Lisinopril—systemic scleroderma	0.00178	0.00304	CcSEcCtD
Plerixafor—Dry mouth—Mycophenolic acid—systemic scleroderma	0.00178	0.00303	CcSEcCtD
Plerixafor—Skin disorder—Leflunomide—systemic scleroderma	0.00177	0.00302	CcSEcCtD
Plerixafor—Hyperhidrosis—Leflunomide—systemic scleroderma	0.00176	0.00301	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Azathioprine—systemic scleroderma	0.00176	0.003	CcSEcCtD
Plerixafor—Abdominal pain—Captopril—systemic scleroderma	0.00175	0.00298	CcSEcCtD
Plerixafor—Nausea—Pentoxifylline—systemic scleroderma	0.00173	0.00296	CcSEcCtD
Plerixafor—Malaise—Lisinopril—systemic scleroderma	0.00173	0.00295	CcSEcCtD
Plerixafor—Diarrhoea—Mometasone—systemic scleroderma	0.00172	0.00294	CcSEcCtD
Plerixafor—Syncope—Lisinopril—systemic scleroderma	0.00172	0.00294	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—RHOB—systemic scleroderma	0.00172	0.0114	CbGpPWpGaD
Plerixafor—CXCR4—Disease—TGFBI—systemic scleroderma	0.00172	0.0113	CbGpPWpGaD
Plerixafor—CXCR4—GPCR ligand binding—EDN1—systemic scleroderma	0.00171	0.0113	CbGpPWpGaD
Plerixafor—Shock—Mycophenolic acid—systemic scleroderma	0.00171	0.00292	CcSEcCtD
Plerixafor—Nervous system disorder—Mycophenolic acid—systemic scleroderma	0.00171	0.00291	CcSEcCtD
Plerixafor—Mental disorder—Mycophenolate mofetil—systemic scleroderma	0.00169	0.00289	CcSEcCtD
Plerixafor—Skin disorder—Mycophenolic acid—systemic scleroderma	0.00169	0.00288	CcSEcCtD
Plerixafor—Loss of consciousness—Lisinopril—systemic scleroderma	0.00169	0.00288	CcSEcCtD
Plerixafor—Hyperhidrosis—Mycophenolic acid—systemic scleroderma	0.00168	0.00287	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.00167	0.00284	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.00166	0.00283	CcSEcCtD
Plerixafor—Flatulence—Mycophenolate mofetil—systemic scleroderma	0.00166	0.00283	CcSEcCtD
Plerixafor—Insomnia—Leflunomide—systemic scleroderma	0.00165	0.00281	CcSEcCtD
Plerixafor—Abdominal distension—Prednisone—systemic scleroderma	0.00165	0.00281	CcSEcCtD
Plerixafor—Paraesthesia—Leflunomide—systemic scleroderma	0.00164	0.00279	CcSEcCtD
Plerixafor—Arthralgia—Lisinopril—systemic scleroderma	0.00164	0.00279	CcSEcCtD
Plerixafor—Dyspnoea—Leflunomide—systemic scleroderma	0.00163	0.00277	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.00162	0.00277	CcSEcCtD
Plerixafor—Discomfort—Lisinopril—systemic scleroderma	0.00162	0.00275	CcSEcCtD
Plerixafor—Dyspepsia—Leflunomide—systemic scleroderma	0.00161	0.00274	CcSEcCtD
Plerixafor—Vomiting—Mometasone—systemic scleroderma	0.0016	0.00273	CcSEcCtD
Plerixafor—Dry mouth—Lisinopril—systemic scleroderma	0.0016	0.00273	CcSEcCtD
Plerixafor—Feeling abnormal—Azathioprine—systemic scleroderma	0.00159	0.00271	CcSEcCtD
Plerixafor—Rash—Mometasone—systemic scleroderma	0.00159	0.00271	CcSEcCtD
Plerixafor—Asthenia—Captopril—systemic scleroderma	0.00159	0.00271	CcSEcCtD
Plerixafor—Dermatitis—Mometasone—systemic scleroderma	0.00159	0.00271	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.00159	0.0027	CcSEcCtD
Plerixafor—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.00158	0.00269	CcSEcCtD
Plerixafor—Headache—Mometasone—systemic scleroderma	0.00158	0.00269	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.00158	0.00268	CcSEcCtD
Plerixafor—Insomnia—Mycophenolic acid—systemic scleroderma	0.00157	0.00268	CcSEcCtD
Plerixafor—Fatigue—Leflunomide—systemic scleroderma	0.00157	0.00268	CcSEcCtD
Plerixafor—Anaphylactic shock—Lisinopril—systemic scleroderma	0.00157	0.00267	CcSEcCtD
Plerixafor—Pruritus—Captopril—systemic scleroderma	0.00157	0.00267	CcSEcCtD
Plerixafor—Paraesthesia—Mycophenolic acid—systemic scleroderma	0.00156	0.00266	CcSEcCtD
Plerixafor—Ill-defined disorder—Mycophenolate mofetil—systemic scleroderma	0.00156	0.00266	CcSEcCtD
Plerixafor—Pain—Leflunomide—systemic scleroderma	0.00156	0.00266	CcSEcCtD
Plerixafor—Constipation—Leflunomide—systemic scleroderma	0.00156	0.00266	CcSEcCtD
Plerixafor—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.00155	0.00264	CcSEcCtD
Plerixafor—Shock—Lisinopril—systemic scleroderma	0.00154	0.00263	CcSEcCtD
Plerixafor—CXCR4—Class A/1 (Rhodopsin-like receptors)—CCL2—systemic scleroderma	0.00154	0.0102	CbGpPWpGaD
Plerixafor—Dyspepsia—Mycophenolic acid—systemic scleroderma	0.00153	0.00261	CcSEcCtD
Plerixafor—Abdominal pain—Azathioprine—systemic scleroderma	0.00153	0.0026	CcSEcCtD
Plerixafor—Skin disorder—Lisinopril—systemic scleroderma	0.00152	0.0026	CcSEcCtD
Plerixafor—Malaise—Mycophenolate mofetil—systemic scleroderma	0.00152	0.00259	CcSEcCtD
Plerixafor—Hyperhidrosis—Lisinopril—systemic scleroderma	0.00152	0.00258	CcSEcCtD
Plerixafor—Diarrhoea—Captopril—systemic scleroderma	0.00151	0.00258	CcSEcCtD
Plerixafor—Syncope—Mycophenolate mofetil—systemic scleroderma	0.00151	0.00257	CcSEcCtD
Plerixafor—Feeling abnormal—Leflunomide—systemic scleroderma	0.0015	0.00256	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.0015	0.00256	CcSEcCtD
Plerixafor—Fatigue—Mycophenolic acid—systemic scleroderma	0.0015	0.00256	CcSEcCtD
Plerixafor—Nausea—Mometasone—systemic scleroderma	0.0015	0.00255	CcSEcCtD
Plerixafor—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.00149	0.00254	CcSEcCtD
Plerixafor—Pain—Mycophenolic acid—systemic scleroderma	0.00149	0.00254	CcSEcCtD
Plerixafor—Constipation—Mycophenolic acid—systemic scleroderma	0.00149	0.00254	CcSEcCtD
Plerixafor—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.00148	0.00252	CcSEcCtD
Plerixafor—Dizziness—Captopril—systemic scleroderma	0.00146	0.00249	CcSEcCtD
Plerixafor—Urticaria—Leflunomide—systemic scleroderma	0.00145	0.00247	CcSEcCtD
Plerixafor—Abdominal pain—Leflunomide—systemic scleroderma	0.00144	0.00246	CcSEcCtD
Plerixafor—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.00143	0.00244	CcSEcCtD
Plerixafor—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.00143	0.00244	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.00143	0.00243	CcSEcCtD
Plerixafor—Hypersensitivity—Azathioprine—systemic scleroderma	0.00142	0.00243	CcSEcCtD
Plerixafor—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.00142	0.00243	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.00142	0.00243	CcSEcCtD
Plerixafor—Insomnia—Lisinopril—systemic scleroderma	0.00142	0.00242	CcSEcCtD
Plerixafor—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.00142	0.00241	CcSEcCtD
Plerixafor—Paraesthesia—Lisinopril—systemic scleroderma	0.00141	0.0024	CcSEcCtD
Plerixafor—Vomiting—Captopril—systemic scleroderma	0.00141	0.0024	CcSEcCtD
Plerixafor—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.0014	0.00239	CcSEcCtD
Plerixafor—Dyspnoea—Lisinopril—systemic scleroderma	0.0014	0.00238	CcSEcCtD
Plerixafor—Rash—Captopril—systemic scleroderma	0.0014	0.00238	CcSEcCtD
Plerixafor—Dermatitis—Captopril—systemic scleroderma	0.00139	0.00238	CcSEcCtD
Plerixafor—Headache—Captopril—systemic scleroderma	0.00139	0.00236	CcSEcCtD
Plerixafor—Dyspepsia—Lisinopril—systemic scleroderma	0.00138	0.00235	CcSEcCtD
Plerixafor—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.00138	0.00235	CcSEcCtD
Plerixafor—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.00137	0.00234	CcSEcCtD
Plerixafor—CXCR4—Disease—HSPG2—systemic scleroderma	0.00137	0.00905	CbGpPWpGaD
Plerixafor—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.00135	0.00231	CcSEcCtD
Plerixafor—Fatigue—Lisinopril—systemic scleroderma	0.00135	0.0023	CcSEcCtD
Plerixafor—Shock—Mycophenolate mofetil—systemic scleroderma	0.00135	0.0023	CcSEcCtD
Plerixafor—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.00135	0.0023	CcSEcCtD
Plerixafor—Hypersensitivity—Leflunomide—systemic scleroderma	0.00134	0.00229	CcSEcCtD
Plerixafor—Pain—Lisinopril—systemic scleroderma	0.00134	0.00228	CcSEcCtD
Plerixafor—Constipation—Lisinopril—systemic scleroderma	0.00134	0.00228	CcSEcCtD
Plerixafor—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.00133	0.00227	CcSEcCtD
Plerixafor—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.00133	0.00226	CcSEcCtD
Plerixafor—CXCR4—Disease—CSK—systemic scleroderma	0.00132	0.00874	CbGpPWpGaD
Plerixafor—Diarrhoea—Azathioprine—systemic scleroderma	0.00132	0.00225	CcSEcCtD
Plerixafor—Haemoglobin—Prednisone—systemic scleroderma	0.00132	0.00224	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—SMAD7—systemic scleroderma	0.00132	0.00868	CbGpPWpGaD
Plerixafor—Nausea—Captopril—systemic scleroderma	0.00131	0.00224	CcSEcCtD
Plerixafor—Abdominal discomfort—Methotrexate—systemic scleroderma	0.00131	0.00224	CcSEcCtD
Plerixafor—Haemorrhage—Prednisone—systemic scleroderma	0.00131	0.00223	CcSEcCtD
Plerixafor—Asthenia—Leflunomide—systemic scleroderma	0.00131	0.00223	CcSEcCtD
Plerixafor—Feeling abnormal—Lisinopril—systemic scleroderma	0.00129	0.0022	CcSEcCtD
Plerixafor—Pruritus—Leflunomide—systemic scleroderma	0.00129	0.0022	CcSEcCtD
Plerixafor—Connective tissue disorder—Prednisone—systemic scleroderma	0.00129	0.00219	CcSEcCtD
Plerixafor—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.00128	0.00218	CcSEcCtD
Plerixafor—Dizziness—Azathioprine—systemic scleroderma	0.00128	0.00218	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.00125	0.00213	CcSEcCtD
Plerixafor—Asthenia—Mycophenolic acid—systemic scleroderma	0.00125	0.00213	CcSEcCtD
Plerixafor—Diarrhoea—Leflunomide—systemic scleroderma	0.00125	0.00213	CcSEcCtD
Plerixafor—Urticaria—Lisinopril—systemic scleroderma	0.00125	0.00212	CcSEcCtD
Plerixafor—CXCR4—Disease—CD247—systemic scleroderma	0.00124	0.00821	CbGpPWpGaD
Plerixafor—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.00124	0.00212	CcSEcCtD
Plerixafor—Abdominal pain—Lisinopril—systemic scleroderma	0.00124	0.00211	CcSEcCtD
Plerixafor—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.00123	0.0021	CcSEcCtD
Plerixafor—Pruritus—Mycophenolic acid—systemic scleroderma	0.00123	0.0021	CcSEcCtD
Plerixafor—Vomiting—Azathioprine—systemic scleroderma	0.00123	0.00209	CcSEcCtD
Plerixafor—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.00122	0.00209	CcSEcCtD
Plerixafor—Rash—Azathioprine—systemic scleroderma	0.00122	0.00208	CcSEcCtD
Plerixafor—Dermatitis—Azathioprine—systemic scleroderma	0.00122	0.00207	CcSEcCtD
Plerixafor—Headache—Azathioprine—systemic scleroderma	0.00121	0.00206	CcSEcCtD
Plerixafor—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	0.00121	0.00206	CcSEcCtD
Plerixafor—Dizziness—Leflunomide—systemic scleroderma	0.00121	0.00206	CcSEcCtD
Plerixafor—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.00119	0.00203	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.00119	0.00202	CcSEcCtD
Plerixafor—Immune system disorder—Prednisone—systemic scleroderma	0.00118	0.00202	CcSEcCtD
Plerixafor—Pain—Mycophenolate mofetil—systemic scleroderma	0.00117	0.002	CcSEcCtD
Plerixafor—Constipation—Mycophenolate mofetil—systemic scleroderma	0.00117	0.002	CcSEcCtD
Plerixafor—CXCR4—GPCR ligand binding—CCL2—systemic scleroderma	0.00117	0.00773	CbGpPWpGaD
Plerixafor—Vomiting—Leflunomide—systemic scleroderma	0.00116	0.00198	CcSEcCtD
Plerixafor—Hypersensitivity—Lisinopril—systemic scleroderma	0.00115	0.00197	CcSEcCtD
Plerixafor—Dizziness—Mycophenolic acid—systemic scleroderma	0.00115	0.00196	CcSEcCtD
Plerixafor—Rash—Leflunomide—systemic scleroderma	0.00115	0.00196	CcSEcCtD
Plerixafor—Dermatitis—Leflunomide—systemic scleroderma	0.00115	0.00196	CcSEcCtD
Plerixafor—Mental disorder—Prednisone—systemic scleroderma	0.00115	0.00196	CcSEcCtD
Plerixafor—Nausea—Azathioprine—systemic scleroderma	0.00115	0.00196	CcSEcCtD
Plerixafor—Headache—Leflunomide—systemic scleroderma	0.00114	0.00195	CcSEcCtD
Plerixafor—Erythema—Prednisone—systemic scleroderma	0.00114	0.00194	CcSEcCtD
Plerixafor—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.00113	0.00193	CcSEcCtD
Plerixafor—Asthenia—Lisinopril—systemic scleroderma	0.00112	0.00192	CcSEcCtD
Plerixafor—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.00112	0.00191	CcSEcCtD
Plerixafor—Pruritus—Lisinopril—systemic scleroderma	0.00111	0.00189	CcSEcCtD
Plerixafor—Vomiting—Mycophenolic acid—systemic scleroderma	0.00111	0.00189	CcSEcCtD
Plerixafor—Haemoglobin—Methotrexate—systemic scleroderma	0.0011	0.00188	CcSEcCtD
Plerixafor—Rash—Mycophenolic acid—systemic scleroderma	0.0011	0.00187	CcSEcCtD
Plerixafor—Dermatitis—Mycophenolic acid—systemic scleroderma	0.0011	0.00187	CcSEcCtD
Plerixafor—Haemorrhage—Methotrexate—systemic scleroderma	0.0011	0.00187	CcSEcCtD
Plerixafor—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.00109	0.00186	CcSEcCtD
Plerixafor—Headache—Mycophenolic acid—systemic scleroderma	0.00109	0.00186	CcSEcCtD
Plerixafor—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.00109	0.00185	CcSEcCtD
Plerixafor—Nausea—Leflunomide—systemic scleroderma	0.00108	0.00185	CcSEcCtD
Plerixafor—Diarrhoea—Lisinopril—systemic scleroderma	0.00107	0.00183	CcSEcCtD
Plerixafor—Ill-defined disorder—Prednisone—systemic scleroderma	0.00106	0.0018	CcSEcCtD
Plerixafor—Dizziness—Lisinopril—systemic scleroderma	0.00104	0.00177	CcSEcCtD
Plerixafor—Nausea—Mycophenolic acid—systemic scleroderma	0.00103	0.00176	CcSEcCtD
Plerixafor—Malaise—Prednisone—systemic scleroderma	0.00103	0.00175	CcSEcCtD
Plerixafor—Syncope—Prednisone—systemic scleroderma	0.00102	0.00174	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—RHOB—systemic scleroderma	0.00102	0.00672	CbGpPWpGaD
Plerixafor—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.00101	0.00172	CcSEcCtD
Plerixafor—Loss of consciousness—Prednisone—systemic scleroderma	0.001	0.00171	CcSEcCtD
Plerixafor—Vomiting—Lisinopril—systemic scleroderma	0.000997	0.0017	CcSEcCtD
Plerixafor—Immune system disorder—Methotrexate—systemic scleroderma	0.000989	0.00169	CcSEcCtD
Plerixafor—Rash—Lisinopril—systemic scleroderma	0.000988	0.00168	CcSEcCtD
Plerixafor—Dermatitis—Lisinopril—systemic scleroderma	0.000988	0.00168	CcSEcCtD
Plerixafor—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000985	0.00168	CcSEcCtD
Plerixafor—Headache—Lisinopril—systemic scleroderma	0.000982	0.00167	CcSEcCtD
Plerixafor—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000972	0.00166	CcSEcCtD
Plerixafor—Arthralgia—Prednisone—systemic scleroderma	0.000971	0.00166	CcSEcCtD
Plerixafor—CXCR4—GPCR downstream signaling—EDN1—systemic scleroderma	0.000968	0.00639	CbGpPWpGaD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000965	0.00164	CcSEcCtD
Plerixafor—Discomfort—Prednisone—systemic scleroderma	0.00096	0.00164	CcSEcCtD
Plerixafor—Mental disorder—Methotrexate—systemic scleroderma	0.00096	0.00164	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—HSPG2—systemic scleroderma	0.000959	0.00634	CbGpPWpGaD
Plerixafor—Erythema—Methotrexate—systemic scleroderma	0.000953	0.00162	CcSEcCtD
Plerixafor—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.00094	0.0016	CcSEcCtD
Plerixafor—Nausea—Lisinopril—systemic scleroderma	0.000931	0.00159	CcSEcCtD
Plerixafor—Anaphylactic shock—Prednisone—systemic scleroderma	0.000931	0.00159	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—CSK—systemic scleroderma	0.000926	0.00612	CbGpPWpGaD
Plerixafor—Shock—Prednisone—systemic scleroderma	0.000916	0.00156	CcSEcCtD
Plerixafor—Nervous system disorder—Prednisone—systemic scleroderma	0.000913	0.00156	CcSEcCtD
Plerixafor—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000908	0.00155	CcSEcCtD
Plerixafor—Skin disorder—Prednisone—systemic scleroderma	0.000904	0.00154	CcSEcCtD
Plerixafor—Hyperhidrosis—Prednisone—systemic scleroderma	0.0009	0.00153	CcSEcCtD
Plerixafor—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000885	0.00151	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—EDN1—systemic scleroderma	0.000879	0.00581	CbGpPWpGaD
Plerixafor—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000873	0.00149	CcSEcCtD
Plerixafor—Rash—Mycophenolate mofetil—systemic scleroderma	0.000866	0.00148	CcSEcCtD
Plerixafor—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000865	0.00147	CcSEcCtD
Plerixafor—Headache—Mycophenolate mofetil—systemic scleroderma	0.00086	0.00147	CcSEcCtD
Plerixafor—Malaise—Methotrexate—systemic scleroderma	0.00086	0.00147	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000848	0.00145	CcSEcCtD
Plerixafor—Insomnia—Prednisone—systemic scleroderma	0.000842	0.00144	CcSEcCtD
Plerixafor—Paraesthesia—Prednisone—systemic scleroderma	0.000836	0.00142	CcSEcCtD
Plerixafor—Dyspepsia—Prednisone—systemic scleroderma	0.00082	0.0014	CcSEcCtD
Plerixafor—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000816	0.00139	CcSEcCtD
Plerixafor—Arthralgia—Methotrexate—systemic scleroderma	0.000812	0.00138	CcSEcCtD
Plerixafor—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000806	0.00137	CcSEcCtD
Plerixafor—Fatigue—Prednisone—systemic scleroderma	0.000803	0.00137	CcSEcCtD
Plerixafor—Discomfort—Methotrexate—systemic scleroderma	0.000802	0.00137	CcSEcCtD
Plerixafor—Constipation—Prednisone—systemic scleroderma	0.000796	0.00136	CcSEcCtD
Plerixafor—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000778	0.00133	CcSEcCtD
Plerixafor—Feeling abnormal—Prednisone—systemic scleroderma	0.000767	0.00131	CcSEcCtD
Plerixafor—Nervous system disorder—Methotrexate—systemic scleroderma	0.000763	0.0013	CcSEcCtD
Plerixafor—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000761	0.0013	CcSEcCtD
Plerixafor—Skin disorder—Methotrexate—systemic scleroderma	0.000756	0.00129	CcSEcCtD
Plerixafor—Hyperhidrosis—Methotrexate—systemic scleroderma	0.000752	0.00128	CcSEcCtD
Plerixafor—Urticaria—Prednisone—systemic scleroderma	0.00074	0.00126	CcSEcCtD
Plerixafor—Abdominal pain—Prednisone—systemic scleroderma	0.000736	0.00125	CcSEcCtD
Plerixafor—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000709	0.00121	CcSEcCtD
Plerixafor—Insomnia—Methotrexate—systemic scleroderma	0.000704	0.0012	CcSEcCtD
Plerixafor—Paraesthesia—Methotrexate—systemic scleroderma	0.000699	0.00119	CcSEcCtD
Plerixafor—Dyspnoea—Methotrexate—systemic scleroderma	0.000694	0.00118	CcSEcCtD
Plerixafor—Hypersensitivity—Prednisone—systemic scleroderma	0.000686	0.00117	CcSEcCtD
Plerixafor—Dyspepsia—Methotrexate—systemic scleroderma	0.000685	0.00117	CcSEcCtD
Plerixafor—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000672	0.00114	CcSEcCtD
Plerixafor—Fatigue—Methotrexate—systemic scleroderma	0.000671	0.00114	CcSEcCtD
Plerixafor—Asthenia—Prednisone—systemic scleroderma	0.000668	0.00114	CcSEcCtD
Plerixafor—Pain—Methotrexate—systemic scleroderma	0.000665	0.00113	CcSEcCtD
Plerixafor—Pruritus—Prednisone—systemic scleroderma	0.000659	0.00112	CcSEcCtD
Plerixafor—Feeling abnormal—Methotrexate—systemic scleroderma	0.000641	0.00109	CcSEcCtD
Plerixafor—Diarrhoea—Prednisone—systemic scleroderma	0.000637	0.00109	CcSEcCtD
Plerixafor—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000636	0.00108	CcSEcCtD
Plerixafor—Urticaria—Methotrexate—systemic scleroderma	0.000618	0.00105	CcSEcCtD
Plerixafor—Dizziness—Prednisone—systemic scleroderma	0.000616	0.00105	CcSEcCtD
Plerixafor—Abdominal pain—Methotrexate—systemic scleroderma	0.000615	0.00105	CcSEcCtD
Plerixafor—CXCR4—Signaling by GPCR—CCL2—systemic scleroderma	0.000601	0.00397	CbGpPWpGaD
Plerixafor—Vomiting—Prednisone—systemic scleroderma	0.000592	0.00101	CcSEcCtD
Plerixafor—Rash—Prednisone—systemic scleroderma	0.000587	0.001	CcSEcCtD
Plerixafor—Dermatitis—Prednisone—systemic scleroderma	0.000586	0.001	CcSEcCtD
Plerixafor—Headache—Prednisone—systemic scleroderma	0.000583	0.000994	CcSEcCtD
Plerixafor—Hypersensitivity—Methotrexate—systemic scleroderma	0.000573	0.000977	CcSEcCtD
Plerixafor—Asthenia—Methotrexate—systemic scleroderma	0.000558	0.000952	CcSEcCtD
Plerixafor—Nausea—Prednisone—systemic scleroderma	0.000553	0.000943	CcSEcCtD
Plerixafor—Pruritus—Methotrexate—systemic scleroderma	0.000551	0.000938	CcSEcCtD
Plerixafor—Diarrhoea—Methotrexate—systemic scleroderma	0.000532	0.000907	CcSEcCtD
Plerixafor—CXCR4—Signaling Pathways—EDN1—systemic scleroderma	0.000519	0.00343	CbGpPWpGaD
Plerixafor—Dizziness—Methotrexate—systemic scleroderma	0.000515	0.000877	CcSEcCtD
Plerixafor—Vomiting—Methotrexate—systemic scleroderma	0.000495	0.000843	CcSEcCtD
Plerixafor—Rash—Methotrexate—systemic scleroderma	0.000491	0.000836	CcSEcCtD
Plerixafor—Dermatitis—Methotrexate—systemic scleroderma	0.00049	0.000835	CcSEcCtD
Plerixafor—Headache—Methotrexate—systemic scleroderma	0.000487	0.000831	CcSEcCtD
Plerixafor—Nausea—Methotrexate—systemic scleroderma	0.000462	0.000788	CcSEcCtD
Plerixafor—CXCR4—Disease—NOS3—systemic scleroderma	0.000452	0.00298	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—CCL2—systemic scleroderma	0.000355	0.00234	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—NOS3—systemic scleroderma	0.000316	0.00209	CbGpPWpGaD
Plerixafor—CXCR4—Disease—TGFB1—systemic scleroderma	0.000299	0.00197	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—MMP9—systemic scleroderma	0.000254	0.00168	CbGpPWpGaD
Plerixafor—CXCR4—Signaling Pathways—TGFB1—systemic scleroderma	0.000209	0.00138	CbGpPWpGaD
